Epigenetic Reprogramming by Decitabine in Retinoblastoma
There is a pressing need to develop innovative treatments for retinoblastoma. Our research revealed that DAC can effectively suppress the growth and progression of retinoblastoma in <i>in vivo</i> models, offering a potential new therapeutic approach to battle this destructive disease. This discovery highlights the impact of this epigenetic therapy in reprogramming tumor dynamics, and thus its potential to preserve both the vision and lives of affected children.
Authors
- Monia Taranta (ORCID: https://orcid.org/0009-0005-4245-2448)
- Lisa Gherardini (ORCID: https://orcid.org/0000-0002-7003-4295)
- Caterina Cinti (ORCID: https://orcid.org/0000-0001-8049-0369)
- Ankush Sharma (ORCID: https://orcid.org/0000-0002-1399-7503)
Institutions
- Oslo University Hospital (NO)
- University of Oslo (NO)
- Istituto di Fisiologia Clinica (IT)
- Institute of Organic Synthesis and Photoreactivity (IT)
- National Research Council (IT)
Publication Details
- Journal
- Frontiers in Bioscience-Landmark
- Published
- 2025-04-25
- DOI
- https://doi.org/10.31083/fbl33386
- Primary Topic
- Epigenetics and DNA Methylation
- Type
- article
- Field-Weighted Citation Impact
- 0.00